share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西維斯健康 | 8-K:重大事件
美股SEC公告 ·  05/01 06:34
Moomoo AI 已提取核心訊息
On May 1, 2024, CVS Health Corporation released its financial results for the first quarter of 2024, reporting a 3.7% increase in total revenues to $88.4 billion compared to the previous year. However, the company experienced a decrease in GAAP diluted EPS from $1.65 to $0.88 and Adjusted EPS from $2.20 to $1.31, primarily due to a decline in the Health Care Benefits segment's operating results, reflecting higher Medicare utilization. CVS Health revised its full-year 2024 guidance, lowering GAAP diluted EPS to at least $5.64 from $7.06, Adjusted EPS to at least $7.00 from $8.30, and cash flow from operations to at least $10.5 billion from $12.0 billion. The revision is based on the assumption that the elevated medical cost trends observed in the first quarter will persist throughout the year. CVS Health's CEO expressed confidence in the company's long-term earnings potential and strategy despite near-term challenges, particularly in the Medicare Advantage sector.
On May 1, 2024, CVS Health Corporation released its financial results for the first quarter of 2024, reporting a 3.7% increase in total revenues to $88.4 billion compared to the previous year. However, the company experienced a decrease in GAAP diluted EPS from $1.65 to $0.88 and Adjusted EPS from $2.20 to $1.31, primarily due to a decline in the Health Care Benefits segment's operating results, reflecting higher Medicare utilization. CVS Health revised its full-year 2024 guidance, lowering GAAP diluted EPS to at least $5.64 from $7.06, Adjusted EPS to at least $7.00 from $8.30, and cash flow from operations to at least $10.5 billion from $12.0 billion. The revision is based on the assumption that the elevated medical cost trends observed in the first quarter will persist throughout the year. CVS Health's CEO expressed confidence in the company's long-term earnings potential and strategy despite near-term challenges, particularly in the Medicare Advantage sector.
2024年5月1日,CVS Health Corporation發佈了2024年第一季度的財務業績,報告總收入與上年相比增長了3.7%,達到884億美元。但是,該公司的GAAP攤薄後每股收益從1.65美元下降至0.88美元,調整後每股收益從2.20美元下降至1.31美元,這主要是由於醫療保健福利板塊的經營業績下降,反映了醫療保險利用率的提高。CVS Health修訂了其2024年全年預期,將GAAP攤薄後每股收益從7.06美元下調至至少5.64美元,調整後每股收益從8.30美元下調至至少7.00美元,運營現金流從120億美元降至至少105億美元。該修訂基於這樣的假設,即第一季度觀察到的醫療費用上漲趨勢將持續到全年。儘管面臨短期挑戰,尤其是在Medicare Advantage領域,但CVS Health的首席執行官仍對公司的長期盈利潛力和戰略充滿信心。
2024年5月1日,CVS Health Corporation發佈了2024年第一季度的財務業績,報告總收入與上年相比增長了3.7%,達到884億美元。但是,該公司的GAAP攤薄後每股收益從1.65美元下降至0.88美元,調整後每股收益從2.20美元下降至1.31美元,這主要是由於醫療保健福利板塊的經營業績下降,反映了醫療保險利用率的提高。CVS Health修訂了其2024年全年預期,將GAAP攤薄後每股收益從7.06美元下調至至少5.64美元,調整後每股收益從8.30美元下調至至少7.00美元,運營現金流從120億美元降至至少105億美元。該修訂基於這樣的假設,即第一季度觀察到的醫療費用上漲趨勢將持續到全年。儘管面臨短期挑戰,尤其是在Medicare Advantage領域,但CVS Health的首席執行官仍對公司的長期盈利潛力和戰略充滿信心。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息